There are two CAR T-cell therapies approved for adults with relapsed or refractory multiple myeloma who have received previous treatments. 

Ciltacabtagene autoleucel (Carvykti, Johnson & Johnson/Legend Biotech): This CAR T-cell therapy is also known as cilta-cel. It has been approved for use since 2022. Currently, cilta-cel is approved for people with relapsed or refractory myeloma who have received one prior treatment, including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide. This means that lenalidomide no longer works to treat the myeloma.

Idecabtagene vicleucel (Abecma, Bristol-Myers Squibb/2seventy bio): This CAR T-cell therapy is also known as ide-cel. It has been approved for use since March 2021. Currently, ide-cel is approved for people with relapsed or refractory myeloma who have received two or more prior treatments, including a proteasome inhibitor, an immunomodulatory agent, and an anti‑CD38 antibody. Ide-cel was the first FDA-approved CAR T-cell therapy for myeloma.